bone injury News
-
Bonesupport – Supplementary Us Denovo Application Submitted
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company has submitted a supplementary De Novo application to the US Food and Drug Administration (FDA) to obtain a market approval for the company’s antibiotic-releasing product CERAMENT® G. The application is specified for the indication osteomyelitis (bone infection) ...
-
Osteoporosis in Older Patients Easy Assessment Easy Assessment of Osteoporosis in Older Patients
According to the National Osteoporosis Foundation (NOF), about 54 million Americans suffer from osteoporosis, presenting low bone mass, and suffering from brittle-bone related injuries, such as fractures, and broken bones. In fact, the disease is responsible for “two million broken bones and $19 billion in related costs every year”, while by the year 2025, “experts predict that ...
By BeamMed Inc.
-
Bonesupport Awarded Synthetic Implantable Products Agreement With Premier
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, has been awarded a group purchasing agreement for Synthetic Implantable Products with Premier. Effective July 1st, the new agreement allows Premier members, at their discretion, to take advantage of pricing and terms pre-negotiated by Premier for CERAMENT® BONE VOID FILLER. “The awarded ...
-
NuShores welcomes a new Quality and Regulatory medical device professional to Little Rock
Little Rock, AR – NuShores Biosciences LLC (NuShores), founded and based in Little Rock, Arkansas, announced today that Mr. Sam Monk has accepted the position of Regulatory and Quality Manager and will move to Little Rock from the Seattle area. Mr. Monk will work closely with C-level management, research scientists, manufacturing, and our Quality and Regulatory team and services providers ...
-
NuShores BioSciences attracts medical devices manufacturing professional to Little Rock
Mark Pelo will lead NuShores’ production of NuCress™ bone regenerative product line. Little Rock, AR – NuShores Biosciences LLC (NuShores), founded and based in Little Rock, Arkansas, announced today that Mr. Mark Pelo has accepted the position of Manufacturing Manager and will move to Little Rock from the Pittsburgh area. He will lead NuShores Generation 1 manufacturing of ...
-
NuShores Biosciences receives new contract for intelligent manufacturing automation of NuCress medical devices
Little Rock, AR – NuShores Biosciences LLC has won a 3-year, $2.8M contract from the Medical Technology Enterprise Consortium (MTEC), a 501(c)(3) biomedical technology consortium associated with the U.S. Army Medical Research and Development Command. The contract will enable NuShores to develop intelligent automated production of its NuCress™ bone void filler scaffold products using ...
-
Stem Cell Agency Awards Almost $4 Million to Develop a Treatment for Spinal Degeneration
Today the governing Board of the California Institute for Regenerative Medicine (CIRM) awarded $3.9 million to Ankasa Regenerative Therapeutics for a promising approach to treat a degenerative condition that can cause chronic, progressive back pain. As we get older, the bones, joints and ligaments in our back become weak and less able to hold the spinal column in alignment. As a result, an ...
-
GRAFTYS announces the extension of its CE mark for its calcium phosphate cements to now include GRAFTYS® HBS and GRAFTYS® Quickset for the indication of subchondral bone marrow lesions around the knee joint (BML)
Aix-en-Provence, September 14th, 2015 – GRAFTYS SA, a company focused on development and commercialization of orthopedic biomaterials, is pleased to announce that it has obtained authorization from its notified body, NSAI (National Standards Authority of Ireland) for European commercialization for two of its cements (GRAFTYS® HBS and GRAFTYS® Quickset) for treatment of bone marrow ...
By Graftys
-
KLISBio to feature engineered silk innovation at AAHS 2022
With the profound impact on patients’ quality of life, peripheral nerve injuries remain at the forefront of treatment challenges for orthopedic surgeons. That’s a driving force behind KLISBio’s SILKBridge®, a first-to-market solution for peripheral nerve repair. KLISBio will introduce SILKBridge® to attendees at the American Association for Hand Surgeons Annual Meeting ...
By KLISBio
-
KLISBio to share innovative tissue-engineered technology at BIO Partnering with JP Morgan
Among the best of new innovations in life sciences and biomedicine being unveiled to investors and healthcare leaders at JP Morgan’s BIO Partnering conference this month is KLISBio’s silk-based biomedical technology. Among the company’s developing portfolio of products is SILKBridge®, a first-to-market, silk-based graft for peripheral nerve repair, which is anticipated ...
By KLISBio
-
Molecular Matrix, Inc. Forms Strategic Alliance with Philosys Healthcare
On August 7, 2019, Molecular Matrix, Inc. (MMI) announced the signing of a Memorandum of Understanding (MOU) with Philosys Healthcare Co., Ltd., a biomedical distribution and manufacturing company based in Seongnam, South Korea. MMI is a biotechnology company that began as a startup at UC Davis, and after more than 10 years of research and development has created a scaffold for bone tissue ...
-
KLISBio to share innovative tissue-engineered technology at LSI 2022 Emerging MedTech Summit
Milan, Italy (March 14, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance to LSI 2022 Emerging MedTech Summit. LSI Annual Meeting will be held March 15 -18, 2022 in Dana Point – CA. KLISBio’s designated attendee to LSI Emerging MedTech Summit ...
By KLISBio
-
KLISBio to feature engineered silk innovation at Biotech Showcase
Investors keen to get involved with a company on the forefront of human tissue regeneration will be interested to visit with KLISBio, an international medtech company bringing its silk-based biomedical technology and the first of their products, SILKBridge®, to the Biotech Showcase Jan. 10-19. KLISBio is leading a revolution in restorative surgical procedures using engineered silk ...
By KLISBio
-
KLISBio to present SILKBridge for peripheral nerve repair and its innovative silk-based tissue-engineered technology platform at 2022 Bio€quity Europe
Milan, Italy (May 11, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance to 2022 Bio€quity Europe. 2022 Bio€quity Europe will be held May 16 -18, 2022 in Milan – Italy. Antonio Alessandrino, CTO and Founder of KLISBio, will be presenting on ...
By KLISBio
-
KLISBio to share its leading-edge silk-based technology platform at 2022 AAOS Annual Meeting
Milan, Italy (March 23, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance 2022 American Academy of Orthopaedic Surgeons Annual Meeting. The event will be held March 22-26 in Chicago -IL. KLISBio’s designated attendee to 2022 AAOS Congress is Jason ...
By KLISBio
-
KLISBio to disclose state-of-the-art tissue-engineered technology platform at 2022 CG Musculoskeletal Conference
Milan, Italy (March 22, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance to 2022 CG Musculoskeletal Conference. Ahead of the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting March 22-26, 2022 in Chicago, Canaccord Genuity will host its CG ...
By KLISBio
-
Locate Bio’s Chondro3 Granted FDA Breakthrough Device Designation
The Company’s second FDA Breakthrough Device designation granted in 2021 Locate Bio, an orthobiologics focused regenerative medicine company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to Chondro3, currently in development as a biomimetic graft for osteochondral lesions. The FDA Breakthrough Device Program is designed ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you